What is a "triple agonist"?

Retatrutide works by mimicking three gut hormones at once: GLP-1, GIP, and glucagon. Each hormone affects the body differently:

• GLP-1 boosts insulin release after meals and curbs appetite.
• GIP also stimulates insulin and may improve how fat tissue handles energy.
• Glucagon raises blood sugar in some contexts but also appears to increase calorie burning.

Existing drugs such as Lilly's tirzepatide (sold as Mounjaro) hit two of these three targets. Retatrutide adds the third, glucagon, which is why researchers speculated it could deliver larger weight loss. In an earlier Phase 2 obesity trial, that speculation appeared to be borne out, with weight reductions that exceeded those of approved medicines.

How solid are the findings?

The results come from a Phase 3 trial, the final stage of human testing before a company can apply for regulatory approval. That is a high evidentiary bar: Phase 3 trials enroll large, diverse groups of patients and compare the drug against placebo or standard treatments.

Still, some caution is warranted:

• The headline announcement precedes full publication, so independent scientists have not yet vetted the numbers.
• "Significant" in clinical trials is a statistical term; it does not automatically mean the effect size is large or clinically decisive.
• Side-effect data — typically nausea and digestive issues for this drug class — will matter greatly for regulators and prescribers.
• One successful trial is a strong start, but approval usually requires multiple Phase 3 studies.

What happens next?

Lilly will need to present detailed results at a medical conference or in a journal, complete its remaining Phase 3 program, and then file with regulators such as the U.S. Food and Drug Administration. If the full data hold up, retatrutide could become a new option for the hundreds of millions of people living with type 2 diabetes worldwide — and potentially a more powerful weight-loss therapy in a separate obesity program.

For now, the drug is not approved anywhere, and patients should not expect it in pharmacies for some time.